# Application of Al18F-NOTA-Pentixafor PET/CT for Primary Aldosteronism

Study · id `cardio:ct-nct06773663` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06773663](<https://clinicaltrials.gov/study/NCT06773663>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT06773663

Browse, organ or system: Blood vessels; Kidneys  
Browse, condition area: High blood pressure  

## In plain language

A phase 1/2 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 150 participants.

## Technical summary

Registry record NCT06773663. Allocation not applicable; no masking; primary purpose diagnostic. Start 2023-12-30 (actual); primary completion 2026-05-30 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose diagnostic
- Phase: Phase 1/2
- Enrolled: 150 participants (planned count; ClinicalTrials.gov record NCT06773663, source copy `cardio:ctgov-nct06773663-2025-02-26`, retrieved 2026-11-18)
- Started: 2023-12-30 (actual) (ClinicalTrials.gov record NCT06773663, source copy `cardio:ctgov-nct06773663-2025-02-26`, retrieved 2026-11-18)
- Primary completion: 2026-05-30 (anticipated) (ClinicalTrials.gov record NCT06773663, source copy `cardio:ctgov-nct06773663-2025-02-26`, retrieved 2026-11-18)
- Completion: 2026-10-30 (anticipated) (ClinicalTrials.gov record NCT06773663, source copy `cardio:ctgov-nct06773663-2025-02-26`, retrieved 2026-11-18)
- Countries: China (ClinicalTrials.gov record NCT06773663, source copy `cardio:ctgov-nct06773663-2025-02-26`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06773663-2025-02-26`, retrieved 2026-11-18)

## The registry's words

- Brief title: Application of Al18F-NOTA-Pentixafor PET/CT for Primary Aldosteronism
- Condition: Primary Aldosteronism
- Condition: Primary Aldosteronism Due to Aldosterone Producing Adenoma
- Intervention (Combination product): Al18F-NOTA-Pentixafor PET/CT
- Lead sponsor: Peking Union Medical College Hospital
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Primary aldosteronism (`cardio:primary-aldosteronism`)
- Registry lists this organization as the lead sponsor: Peking Union Medical College Hospital (`cardio:org-peking-union-medical-college-hospital`)

## Provenance

Content hash: 56a60ae3eee5b553e60dcd6827684b04b9eee5c2976abc26f3598352740a65ae
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
